3D printing for cancer treatment Archives - Perfect 3D Printing Filament

Japanese researchers Jin Liu, Tatsuaki Tagami, and Tetsuya Ozeki have completed a recent study in nanomedicine, releasing their findings in “Fabrication of 3D Printed Fish-Gelatin-Based Polymer Hydrogel Patches for Local Delivery of PEGylated Liposomal Doxorubicin.” Experimenting with a new drug delivery system, the authors report on new potential for patient-specific cancer treatment.

The study of materials science continues to expand in a wide range of applications; however, bioprinting is one of the most exciting techniques as tissue engineering is expected to lead to the fabrication of human organs in the next decade or so. Such research has also proven that bioprinting may yield much more powerful drug delivery whether in using hybrid systems, multi-drug delivery systems, or improved scaffolds.

Here, the materials chosen for drug delivery are more unique as the researchers combined printer ink with semi-synthesized fish gelatin methacryloyl (F-GelMA)—a cold fish gelatin derivative.

In providing aggressive cancer treatment to patients, the use of doxorubicin (DOX) is common as an anti-carcinogen for the treatment of the following diseases:

Breast cancer
Bladder cancer
Kaposi’s sarcoma
Lymphoma
Acute lymphocytic leukemia

DOX may also cause serious cardiotoxicity, however, despite its use as a broad-spectrum drug. As a solution, PEGylated liposomal DOX, Doxilhas been in use for treatment of cancer with much lower cardiotoxity. The nanomedicine has also been approved by the FDA, and is used for targeting local tumors; for instance, this type of drug delivery system could be suitable for treating a brain tumor.

“PEGylating liposomes can prolong their circulation time in blood, resulting in their passive accumulation in cancer tissue, called the enhanced permeability and retention effect,” state the authors.

Using a 3D bioprinter, the authors developed liposomal patches to be directly implanted into cancerous cells.

(a) Synthesis of fish gelatin methacryloyl (F-GelMA). (b) Hybrid gel of cross-linked F-GelMA and carboxymethyl cellulose sodium (CMC) containing PEGylated liposome. The reaction scheme was prepared in previous studies

“We used a hydrogel containing semi-synthetic fish-gelatin polymer (fish gelatin methacryloyl, F-GelMA) to entrap DOX-loaded PEGylated liposomes. Fish gelatin is inexpensive and faces few personal or religious restrictions,” stated the authors.

Fish gelatin has not been used widely in bioprinting, however, due to low viscosity and rapid polymerization. To solve that problem, the authors created a bioink composite with elevated viscosity.

Viscous properties of drug formulations used as printer inks. (a) The appearance of F-GelMA hydrogels containing different concentrations of CMC. (b) The viscosity profiles of F-GelMA hydrogels containing different concentrations of CMC. The data represent the mean ± SD (n = 3).

And while hydrogels are generally attractive for use due to their ability to swell, for this study, the researchers fabricated a variety of different materials—with the combination of 10% F-GelMA and 7% carboxymethyl cellulose sodium (a thickening agent) showing the highest swelling ratio.

Swelling properties of hydrogels after photopolymerization. (a) Swelling ratio of different concentrations of F-GelMA. (b) Swelling ratio of mixed hydrogel (10% F-GelMA with different concentrations of CMC). The data represent the mean ± SD (n = 3).

Design of the different 3D geometries: (a) cylinder, (b) torus, and (c) gridlines.

Patches were printed in three different sample shapes, using a CELLINK bioprinter syringe as the authors tested drug release potential in vivo. Realizing that surface area, crosslinks density, temperature, and shaker speed would play a role, the team relied on a larger surface volume for more rapid release of drugs.

Printing conditions of patches.

While experimenting with the torus, gridline, and cylindrical sample patches, the researchers observed gridline-style patches as offering the greatest potential for sustained release.

Drug release profiles of liposomal doxorubicin (DOX). (a) Influence of shape on drug release. The UV exposure time was set to 1 min. (b) Influence of UV exposure time on drug release. The gridline object was used for this experiment. The data represent the mean ± SD (n = 3).

“These results indicate that CMC is useful for adjusting the properties of printer ink and is a useful and safe pharmaceutical excipient in drug formulations. We also showed that drug release from 3D-printed patches was dependent on the patch shapes and UV exposure time, and that drug release can be controlled. Taken together, the present results provide useful information for the preparation of 3D printed objects containing liposomes and other nanoparticle-based nanomedicines,” concluded the authors.

[Source / Images: ‘Fabrication of 3D Printed Fish-Gelatin-Based Polymer Hydrogel Patches for Local Delivery of PEGylated Liposomal Doxorubicin’]

The post 3D Printed Medicine Uses Fish Gelatin to Deliver Cancer Treatment appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.

In the recently published ‘A Drug-Eluting 3D-Printed Mesh (GlioMesh) for Management of Glioblastoma,’ Canadian researchers take on the topic of using 3D printing for better treatment of glioblastoma (GBM) as current surgical procedures, radiation therapy, and medications still do not seem to be making an impact on survival rates.

In this study, the researchers offer a new method for treatment, via GlioMesh, made from 3D printed hydrogels that are filled with temozolomide microparticles (TMZ). GBMs are one of the most aggressive forms of brain cancer, affecting nearly 50 percent of patients with brain tumors within the US. Today, there is less than a ten percent chance of survival over five years for patients diagnosed with GBM.

“The standard therapy for GBM is maximal safe surgical resection, followed by radiation and chemotherapy with temozolomide (TMZ) for 6 months,” explain the researchers. “After the radiotherapy is finished, the monthly administration of TMZ is maintained for 6 months up to one year. Together, these typically add only months of additional survival. Even with the current advances in microsurgical techniques, tumor recurrence is the norm, typically occurring within 1–2 cm of the original tumor border.”

Obstacles in treating/managing GBM include:

Issues with complete removal of the tumor, often spread in ‘finger-like projections’
Ineffectiveness of chemotherapy to treat areas deep within brain tissue
Challenges due to the blood-brain/tumor barrier
Drug-resistant characteristics of GBM cancer stem cells

The researchers are striving to:

Increase the amount of survival time
Increase long-term survival rate
Improve quality of life for patients

While TMZ can overcome the blood-brain barrier, high doses are often required, and side effects can be brutal; however, the researchers explain that is it possible to bypass some of these challenges with localized delivery of the drug. With the drug-releasing mesh developed for this study (consisting of alginate hydrogel and laden with TMZ‐loaded PLGA microspheres), the researchers found they could release TMZ over the tumor site for seven weeks at a time.

Schematic demonstration of GlioMesh and its fabrication process. A) O/O emulsion solvent evaporation technique for fabrication of TMZ‐loaded PLGA microspheres with high encapsulation efficiency. B) Preparation of bioink. C) 3D printing of alginate mesh containing TMZ‐loaded PLGA microspheres. D) Cross‐linking of the printed mesh. E) 3D printed mesh, laden with TMZ‐releasing PLGA microspheres. F) The efficacy of GlioMesh in treatment of GBM was evaluated by various studies on U251 and U87 human GBM cells.

“Fabrication of a porous mesh by 3D printing is an enabling technology that offers the advantages of higher mass transport of the drug to the surrounding tissue due to higher surface to volume ratios, better cellular infiltration, and enhanced delivery of nutrients and oxygen to the underlying tissue,” explained the researchers.

The study showed poor ‘encapsulation efficiencies’ of 0.87 ± 0.52%, and 1.34 ± 0.03% for the microspheres prepared with O/W and W/O/W emulsion, respectively. This had also been the result for previous researchers engaging in similar work. Further refinements did not show much of an improvement.

Characterization of PLGA microspheres prepared with different PLGA concentrations. A) SEM images of blank and TMZ‐loaded PLGA microspheres prepared with 1.25%, 5%, and 10% PLGA concentration. Scale bars are 500 µm. B) Size distribution of blank and TMZ‐loaded PLGA microspheres fabricated with various PLGA concentrations. C) Average size of blank and TMZ‐loaded PLGA microspheres prepared with 1.25%, 5%, and 10% PLGA concentration. Increase in PLGA concentration resulted in fabrication of microspheres with larger average diameter. Each data point represents the average ± SD. *p < 0.0005.

As the researchers increased print-head pressure, they were finally able to deposit more alginate, increasing fiber diameter. Greater control over the 3D printed meshes occurred with the proper amount of viscosity. Adding polymeric microspheres also helped encourage longer TMZ release at the tumor.

Characterization of 3D bioprinted alginate mesh. A) Photographic images of TMZ‐releasing alginate mesh. Right image shows the flexibility of GlioMesh, which is a suitable feature for a brain implant to comply with the underneath irregularly shaped tissue. B) SEM image of GlioMesh showing its porous structure. C) The effect of print‐head pressure on the fiber characteristics. Higher pressure on the nozzle resulted in larger fiber diameter and smaller surface‐to‐volume ratio. Microscopic images of alginate mesh printed with 40, 80, and 120 kPa pressure. D) The effect of printing speed on the characteristics of the 3D bioprinted fiber. Printing with higher speed resulted in decreased fiber diameter and increased surface‐to‐volume ratio. Microscopic images of alginate meshes printed with 250, 350, and 450 mm min−1 of printing speed. E) The effect of microsphere concentration on the fiber diameter in the 3D printed meshes. Fiber diameter increased by higher microsphere densities. Microscopic images of GlioMesh printed with 1, 3, and 6 mg mL−1 of microsphere concentration. Each data point represents the average ± SD with n = 6. *p < 0.005 and **p < 0.0005.

“GlioMesh demonstrated a sustained release of TMZ over 56 days, which circumvents the need for frequent oral administration of this chemotherapy drug in GBM patients,” concluded the researchers. “GlioMesh showed superior cytotoxic effect over free TMZ due to the preservation of the drug from degradation over the course of treatment and maintaining the level of autophagy in GBM cells.

“Furthermore, higher degree of mitochondrial damage was achieved by sustained delivery of TMZ in comparison with free TMZ. All in all, GlioMesh holds great promise in the management of GBM by reducing the side effects of chemotherapy, circumventing the BBB and associated challenges, and providing more flexibility toward using a combinational therapy approach that is tailored to each patient.”

The amount of cancer research and treatment today that includes 3D printing in its successes is staggering—from microfluidic devices to the printing of tumors, microtumors, and more for assistance in critical research.

What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com.

[Source / Images: ‘A Drug-Eluting 3D-Printed Mesh (GlioMesh) for Management of Glioblastoma’]

The post Canada: University Researchers 3D Print GlioMesh to Treat Brain Cancer appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.